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Abstract Anti-tumor electrochemotherapy, which consists in
increasing anti-cancer drug uptake by means of electropora-
tion, is now implanted in about 140 cancer treatment centers in
Europe. Its use is supported by the English National Institute
for Health and Care Excellence for the palliative treatment of
skin metastases, and about 13,000 cancer patients were treated
by this technology by the end of 2015. Efforts are now
focused on turning this local anti-tumor treatment into a
systemic one. Electrogenetherapy, that is the electroporation-
mediated transfer of therapeutic genes, is currently under clinical
evaluation and has brought excitement to enlarge the anti-cancer
armamentarium. Among the promising electrogenetherapy
strategies, DNA vaccination and cytokine-based immunothera-
py aim at stimulating anti-tumor immunity. We review here the
interests and state of development of both electrochemotherapy
and electrogenetherapy. We then emphasize the potent benefi-
cial outcome of the combination of electrochemotherapy with
immunotherapy, such as immune checkpoint inhibitors or
strategies based on electrogenetherapy, to simultaneously
achieve excellent local debulking anti-tumor responses and
systemic anti-metastatic effects.
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1 Introduction
Many methods have been developed for in vitro and in vivo
applications to deliver molecules inside the cells. Although
very efficient, viral methods are rather restricted to nucleic
acid transfer and have brought many safety concerns, while
chemical methods lack efficiency for localized in vivo appli-
cations. Among the physical methods, electroporation has
raised a great excitement over the last two decades [1, 2].
Indeed, the use of electricity to manipulate cells or target tis-
sues appears quite seducing. Electroporation is increasingly
being used among the scientific and the medical communities,
as it is a safe and efficient technique to transfer a variety of
material (e.g., nucleic acids, cytotoxic drugs, and ions) into
target cells and tissues without harming them. This reviewwill
first give the readers an overview of electroporation-based
therapeutic strategies and will then highlight the rationale of
combining them with immunotherapy in the context of anti-
cancer treatments.
2 Insights into cell electroporation and its medical
applications
Pioneer works related to electroporation (also called
electropermeabilization) started in 1968 with Sale and
Hamilton who showed that the application on cells of intense
electric fields induces the release of intracellular molecules
that are unable to cross by themselves the cell membrane
under physiological conditions [3]. Nearly 15 years later,
Neumann and collaborators managed to transfer exogenous
molecules (i.e., DNA) into mouse lyoma cells using electro-
poration [4], thereby giving rise to a wide range of applica-
tions for this technology.
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Electroporation is a generic term used to describe the
phenomenon of increased permeability of the cell membrane
following the application of short and intense electric pulses
(EPs). Here, in Sects. 2–5, we will discuss the biomedical
applications of electric fields preserving cell viability (Fig. 1a).
The achievement of membrane electroporation depends on the
biophysical properties of the cell membrane and those of the
cell-surrounding medium [1]. Although intense researches are
being conducted to understand the mechanisms underlying
membrane electroporation, these are still speculative.
Even though electroporation is a promising approach for
the treatment and the prevention of several pathologies, cancer
is nowadays the major indication of electroporation-based
therapies [2]. The following three different medical applica-
tions of electroporation have already been developed and
brought to clinics:
– Electroporation to transfer drugs and small molecules
(Fig. 1b), the anti-cancer electrochemotherapy (ECT;
see Sect. 2) is the combination of electroporation and
cytotoxic drugs that do not freely cross the plasma
membrane. ECT was the first application that reached
the clinical stage [5, 6]. ECT works very efficiently
and without major side effects. It selectively kills the
tumor cells and spares the normal non-dividing cells
in the volume exposed to the electroporating EPs
Fig. 1 Principle of biomedical applications of electroporation. a
Electroporation consists in the delivery of a limited number of short and
intense electric pulses which are defined by an intensity E and a duration
t. Above a certain threshold of the E and/or t parameters, cell membrane
defects appear and result in cell permeabilization. After a given lag
time, cell membrane integrity is restored leading to cell survival. b
Electrochemotherapy consists in the delivery of short and intense
electric pulses following the administration of non- or low-permeant
cytotoxic drugs, such as bleomycin. Cell membrane permeabilization
permits the drug to enter the target cells and eventually to trigger cell
death through multiple DNA breaks, which are lethal for dividing
cells. c Electrogenetherapy relies on gene electrotransfer, namely, the
conjunction of DNA delivery and electroporation. Gene electrotransfer
can be achieved by first permeabilizing the cell membrane thanks to
short and intense electric pulse deliveries and second by driving
electrophoretically the DNA toward the electroporated membrane
thanks to a long and low-voltage electric pulses. It is then expected
that a protein of interest is produced and epitope presentation occurs
on MHC molecules. d Irreversible electroporation consists in the use
of excessive electroporation to cause cell death. Different approaches
can lead to this outcome including the use of very long or very
intense electric pulses or the use of too many of electric pulses
whose characteristics are similar to those used in viability-preserving
electroporation strategies
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(usually trains of eight short pulses of 100-μs duration).
However, ECT remains a local treatment with no obvious
effects on distant metastases.
– Electroporation to transfer nucleic acids inside the
cells (Fig. 1c), the electroporation-based gene transfer,
that, if a therapeutic outcome is desired, constitutes a
subcategory of gene therapy; the electroporation-
mediated gene therapy, namely, electrogenetherapy
(EGT; see Sect. 3), is an approach rapidly expanding
in cancer and non-cancer therapeutic domains [7, 8].
It covers some of the classical gene therapy objectives
with no virus use. The EPs used are often longer
(tens of milliseconds), and combinations of short and
long EPs are also delivered. In the anti-cancer field,
the two most exciting EGT applications are cytokine
therapy and non-viral DNA vaccination, both at the
crossing of electroporation and immunology.
– Electroporation to kill cells (Fig. 1d), the irreversible elec-
troporation (IRE) is also developing for liquid steriliza-
tion in the food and environment industries, among other
uses [2]. In this application, what is sought is cell death
triggering due to excessive electroporation. This local
ablative treatment is not selective against the tumor
cells, killing also the normal cells in the volume of
tissue exposed to the EPs. Because of its absence of
selectivity, IRE is not developed in this review.
The use of very short EPs of a duration of tens to hundreds
of nanoseconds is also being explored [2], with purposes (e.g.,
manipulation of internal cell membranes and cell death induc-
tion) which are also beyond the scope of this article.
Section 4 of this review highlights the preclinical data
showing the potential synergistic effect of the combination
of ECTwith immunotherapy strategies, including those based
on EGT. In Sect. 5, we report recent clinical data suggesting
that the promising alliance of anti-cancer electrochemotherapy
with immunotherapy is already coming to the reality.
3 Electrochemotherapy
As ameans to increase the uptake of cytotoxic drugs by cancer
cells, electroporation is used in the context of anti-tumor ECT.
3.1 Bases of ECT
ECT is a non-thermal and non-ablative local treatment of solid
tumors consisting in the application of EPs combined with the
administration of non-/low-permeant anti-cancer molecules
[2, 9, 10]. The proof of concept of ECT has been made in
many in vitro and in vivo models, and the treatment is now
routinely applied in humans.
The EPs, locally delivered to the whole volume of the nod-
ule, are meant to reversibly permeabilize the cells located in
the treated region, without killing them. The anti-cancer drug,
administered directly into the tumor or systemically, can then
enter the electroporated target cells without restrictions to
achieve its cytotoxic activity (Fig. 1b).
The main advantage of ECT over other chemical-based
anti-cancer treatments is to selectively target tumor cells, on
the one hand, by applying EPs locally, and on the other hand,
by using an anti-cancer drug displaying specific cytotoxicity
toward dividing cells, which are mainly the cancer cells. Two
conditions are required for ECT to be efficient; first, although
low, a sufficient concentration of drug has to be present in the
tumor, and second, the whole tumor area has to be covered by
a permeabilizing electric field. Under these conditions, ECT
eliminates the cancer cells while sparing normal cells and
histological structures.
3.2 Drugs used in ECT protocols
In late 1980s, Mir et al. [11] described the utility of EP deliv-
ery in vivo in conjunction with anti-cancer drugs. The require-
ment for a drug to be used in combination with EPs is first to
poorly (or not at all) diffuse through the plasma membrane
and second to possess a very high intrinsic cytotoxic potential.
Indeed, the ECT principle is to potentiate the drug entrance at
the location of the EP delivery while sparing non-
electroporated areas. Two anti-cancer molecules have met
these prerequisites and are currently used in the clinical prac-
tice of ECT, bleomycin and cisplatin [2, 10]. These drugs,
once internalized into cells via the local delivery of EPs, gen-
erate direct DNA lesions, either both single-strand and
double-strand DNA breaks (if bleomycin is used) or adducts
and intrastrand and interstrand DNA bonds (if cisplatin is
used), ultimately leading to cell death. In cells not exposed
to EPs, bleomycin enters in very low amounts in a few cell
types (e.g., lymphoma cells), possibly through a receptor-
mediated endocytotic pathway [12]. After cell electroporation,
large amounts of the cytotoxic molecules enter cells by diffu-
sion, regardless of the cell type. Electroporation thus turns
bleomycin and cisplatin into very efficient drugs in all tumor
types, as verified in preclinical and clinical studies.
Bleomycin and cisplatin administrations, associated with
EP delivery, have shown robust anti-cancer activities in vitro,
in vivo, and in humans. In vitro, the half maximal inhibitory
concentration (IC50) of cisplatin was decreased by up to 13-
fold when using EPs. Notably, an increased cytotoxicity to the
drug was also observed in cisplatin-resistant cell lines [13].
Even more interestingly, the combination of bleomycin with
EPs decreased the IC50 by up to several hundred folds. The
low dose of anti-cancer drug used in ECT protocols, along
with the local delivery of the EPs, enables the specific toxicity
of the drug toward cancer cells and the absence of systemic
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side effects. Indeed, both normal and cancer cells are perme-
abilized in the treated region and thus will get their DNA
cleaved by the several hundreds of bleomycin molecules in-
ternalized in the electroporated cells in the classical ECT pro-
tocols [14]. This number of bleomycin molecules is able to
generate enough DNA breaks to drive cell death upon cell
division [15] (as is defined, the mitotic cell death) but is not
sufficient to drive metabolic cell death. Consequently, normal
cells, that are quiescent cells, are spared and systemic
side effects are thus rarely observed. In support of this
and contrary to many other anti-cancer drugs, no diges-
tive side effects and neither immunosuppression nor
myelosuppression have been reported, in particular fol-
lowing systemic bleomycin administration at the specific
dose used in ECT protocols. Recently, an alternative to the use
of cytotoxic drugs has been proposed through the intratumoral
administration of a concentrated calcium solution, associated
with EP delivery [16, 17].
3.3 Clinical use of ECT
The first clinical evaluation of ECT with bleomycin was per-
formed in 1991 at Institut Gustave-Roussy (Villejuif, France)
in patients affected by head and neck carcinomas [5]. This
study confirmed the safety and the feasibility of ECT in
humans. Since then, a wide range of tumors has been treated
by ECT, mainly using bleomycin [10, 18, 19]. These now
include primary tumors (basal cell carcinoma) and metastases
of head and neck carcinomas, Kaposi’s sarcoma, breast ade-
nocarcinoma, and melanoma. Clinical trials are nowadays ad-
dressing the treatment of deep-seated tumors (primary pancre-
atic carcinoma and bone, liver, and brain metastases). ECT is
particularly indicated to treat bleeding nodules as the treat-
ment immediately stops bleedings and/or hemorrhages.
Indeed, ECT demonstrates potent anti-vascular effects [20].
A transient vasoconstriction is observed following EP deliv-
ery alone, and moreover, the endothelial cells forming tumor
blood vessels are also sensitive to ECT (as any proliferative
cell in the treated region). Consequently, these phenomena
result in tumor starvation (lack of oxygen and growth factors)
and thus contribute to cancer cell death.
In 2006, the multicentric European Standard Operating
Procedures of ECT (ESOPE) study [21] established the stan-
dard operating procedures for ECT use in the clinic [22]. As
reported, a train of eight EPs of 100 μs and of appropriate field
amplitude has to be delivered using either invasive (EPs of
1000 V/cm) or non-invasive electrodes (EPs of 1300 V/cm),
depending on the depth and on the size of the nodules to treat.
This study also reported that a complete tumor regression was
observed in 73·7 % of the treated nodules and the overall
objective response was 84·8 %, 6 months after one single
ECT session. Finally, this study emphasized the safety and
the efficiency of the procedure, especially when bleomycin
was injected intravenously, although an intratumoral injection
can be considered. Contrariwise, due to systemic side effects
associated with the intravenous administration of cisplatin, its
use in ECT protocols is restricted to intratumoral injections
only.
Since the ESOPE study, many other clinical trials have
been performed, and overall, the rate of complete tumor re-
gressions following one single ECT treatment is 60 % (85 %
of objective response), although this percentage varies among
the tumor types [23]. Moreover, it should be noted that after
ECT, local relapses are rarely observed [21, 24–26], and if so,
the relapse occurs many years later, demonstrating a local
long-lasting response to ECT [27].
Side effects of ECT are minimal and include erythema,
edema, superficial epidermal erosion, and relative pain and
muscle contraction at the time of the EP delivery [23]. As a
very low dose of chemotherapeutic is used, these side effects
are all due to the EP delivery or to the use of invasive elec-
trodes and are easily manageable by the administration of
appropriate anesthesia and myorelaxants.
The only contraindication to ECT regards known allergy
to the drug used [22]. Moreover, if the patient has reached
a well-known cumulative dose of bleomycin (400,000 IU
bleomycin/m2 potentially resulting in pulmonary fibrosis),
the use of cisplatin has to be considered.
In summary, for the local treatment of superficial tumors of
numerous histological origins, ECT is safe (displaying only
manageable minor local side effects) [21], rapid (one session
lasts about 25 min) [21], and very efficient (85 % of local
objective response after one single ECT session) [23].
Development of new electrodes is ongoing in order to apply
ECT protocols on tumors located in deep-seated organs, such
as colon, liver, bone, and brain, and recent clinical trials reveal
that the treatment is also very efficient for these non-
superficial tumors [23]. Moreover, from an economic point
of view, ECT is a cost-effective treatment that enhances nota-
bly the quality of life of the treated patients [28].
Nowadays, ECT is used in routine in about 140 European
cancer centers. ECT is used in particular when a palliative
treatment of cutaneous and subcutaneous metastases is
sought, when tumor burden has to be reduced before sur-
gery or when the surgery would generate non-esthetic scars
(e.g., in the head and neck areas) [10, 23]. It is reimbursed
in Austria, Denmark, Germany, Italy, Portugal, Slovenia,
Spain, Switzerland, and in the UK. Efforts are being made
to broaden the range of cancer types treated by ECT, in
particular for the treatment of primary tumors. In addition,
an increasing number of European oncology centers are
adopting this treatment regimen, as reported at the 2010 and
2013 International Users’ Meetings (www.igeamedical.com).
By the end of 2015, about 13,000 cancer patients were treated
by ECT. Finally, the English National Institute for Health and
Care Excellence provided in 2013 interventional procedure
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guidance, emphasizing the beneficial outcome of ECT as a
palliative treatment of skin metastases (www.nice.org.uk).
4 Electrogenetherapy
Not only drugs but also nucleic acids can be transferred into
target cells via the delivery of EPs [4]. The strategy is called
gene electrotransfer, and if a therapeutic outcome is desired, it
constitutes a subcategory of gene therapy, the electroporation-
mediated gene therapy, namely, EGT.
4.1 EGT: gene therapy using electrotransfer
The transfection of target cells by naked DNA only is quite
low [29] and variable [30] in vivo. Thus, efforts were made to
improve the transfection efficiency in order to obtain suffi-
cient protein production. Several strategies are currently avail-
able to enhance the transfer of DNA into target cells. One
discriminates viral and non-viral gene transfer methods, the
latter including chemical and physical methods [7, 8].
Viral vectors are endowed with cell-targeting capacity and
are highly effective at transducing target cells. However, the
size of the transgene that can be inserted into viral particles is
limited; some of these vectors are highly immunogenic (thus
preventing multiple administrations); concerns were raised
about insertional mutagenesis; and last but not least, GMP-
grade viral vectors are expensive to produce.
Contrary to viral vectors, most non-viral vectors are not
able to specifically recognize the target cells. Hence, the
DNA has to be brought close to the target cell environment,
and then, a means to enable the crossing of the plasma mem-
brane is required to bring the DNA into the cells. Chemical
vectors are based on cationic lipids or polymers forming
complexes with DNA. However, chemical methods are
associated with high cell toxicity and low efficiency, in
particular in vivo. Physical methods (e.g., microinjection,
gene gun, sonoporation, and gene electrotransfer) are par-
ticularly interesting since large transgenes can be trans-
ferred into target cells; the gene expression is transitory
and the risk of insertional mutations is dramatically decreased
[7]. Gene electrotransfer is one of the most efficient non-viral
techniques and has proven its efficiency in many tissues,
should they be superficial (e.g., skin) or internal (e.g., liver
and muscle). The main limit to the use of gene electrotransfer
is related to its application to not easily accessible organs.
Finally, gene electrotransfer ensures a local confinement
of the DNA [31], preventing the germ line from being
transfected and the subsequent transmission of the exogenous
genes along generations.
In the context of gene therapy, normal cellular functions
can be restored and therapeutic or immunogenic proteins can
be endogenously produced. Among the protein-encoding-
based gene therapy approaches, the administration of genes
encoding growth factors, cytokines, costimulatory proteins,
antibodies, or antigens appears quite seducing compared to
classical protein therapy [32]. In particular, gene therapy is
highly cost-effective as it does not require many administra-
tions and it is associated with a much less variable protein
concentration due to a sustained production by the organism.
Moreover, the use of naked DNA is very interesting
since GMP-grade DNA is much cheaper to produce
than GMP-grade proteins. Besides, proteins produced
in situ are fully functional since the endogenous produc-
tion ensures the correct folding and post-translation
modifications. As for other gene therapy approaches,
EGT is a promising method to obtain a therapeutic out-
come following the delivery of naked nucleic acids into
the cell interior by using gene electrotransfer [33].
4.2 Mechanisms of gene electrotransfer
Gene electrotransfer is a multistep process (Fig. 1c). First of
all, DNA has to be injected at the expected site of gene trans-
fer. Then, EPs have to be delivered. Notably, the optimization
of the gene electrotransfer procedure enables the use of a re-
duced quantity of injected DNA to achieve the desired gene
expression. Optimally, the gene electrotransfer protocol (field
amplitude and duration of the EPs) has to be set up in order for
the EPs to achieve two different types of effects [34]. In the
first place, EPs have to permeabilize transiently the cell mem-
brane. Then, EPs have to drive electrotrophoretically the DNA
toward the electroporated cells. According to one commonly
used protocol [35], the combination of short (100 μs) and
intense EPs (HV EPs) and long (hundred(s) of milliseconds)
and less intense EPs (LV EPs) constitutes a very safe
procedure associated with a very good gene expression.
The delivery of HV EPs or LV EPs alone is also used
in the field of gene electrotransfer and can also be asso-
ciated with increased gene expression.
Regarding in vivo studies, gene electrotransfer has been
tested in various animal species (mice, rats, rabbits, and pets)
and tissue-specific protocols have been set up for various tis-
sues, including skin, muscle, tumor, liver, cornea, lung, kid-
ney, brain, bladder, and testis [36, 37]. In particular, skin is
interesting for vaccination purposes as this organ is densely
populated in antigen-presenting cells (APCs), such as dendrit-
ic cells (DCs) [38]. However, contrary to muscle, which is
considered as a protein factory, transgene expression in skin
does not last over months but only over few weeks and at
lower levels [35, 36]. Finally, tumor cells may also receive
DNA but expression is transient as they divide rapidly
and lose the plasmid by dilution over cell divisions.
Hence, tumor cell transfection is useful for a short-term
production of proteins, such as cytokines exhibiting anti-
cancer properties (e.g., interleukin 12).
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4.3 EGT: from bench to bedside
Since 1989 and the first approval of a clinical trial involving
gene therapy, more than 2000 clinical trials have been
launched and more than 60 % of the indications relate to
cancer (http://www.abedia.com/wiley). Among the 3700
gene therapy-related clinical trials currently in process, 61
are based on EGT [39]. The two most advanced EGT strate-
gies are related to immunotherapy, namely, DNA vaccination
and cytokine-based anti-cancer therapies. We focus on these
two specific applications of EGT because of the interest of
their association with ECT, as discussed in Sect. 4 of this
review.
4.3.1 Electroporation-based DNA vaccination
DNA vaccination consists in the administration of a DNA
encoding an antigen of interest to protect the body against
pathogens or cancer cells exposing this antigen [40].
Eventually, the encoded antigen will be responsible for
the generation of a pool of specific B and T cells, from
which some will remain as memory cells for long-term
protection. Tumor-specific CD8+ T cell generation, asso-
ciated with the secretion of Th1 cytokines (e.g., tumor
necrosis factor α (TNFα) and interferon γ (IFNγ)), is
desired in the context of anti-cancer therapy [41, 42].
DNA vaccination technology has been developed for a
wide range of applications, from laboratory tools to licensed
veterinary vaccines.
One of the major factors influencing the DNA vaccination
outcome is the level of expression of the antigen administered
in its encoding form. Indeed, the poor DNA uptake by the
target cells was one of the main reasons that explained the
failure in translating to humans the promising results obtained
in small rodents with naked DNA administration [40, 43].
Consequently, it is not surprising that EPs are increasingly
used for the development of new DNA vaccination strategies
[44, 45]. Several studies demonstrated that the immunogenic-
ity of DNAvaccines was greatly increased by electroporation,
as compared with DNA vaccine injection alone, in rodent
models and in larger animals. A striking example refers to a
DNA encoding the prostate-specific antigen (PSA) in the con-
text of prostate cancer [46]. Roos et al. demonstrated that the
antigen expression was enhanced by up to 1000-fold when
DNA injection was combined with electroporation. This also
led to an improved PSA-specific T cell priming. This DNA
vaccine is currently being tested in a phase I/II clinical trial
(NCT00859729).
Regarding DNA vaccination performed in humans,
not less than 51 clinical trials involving electroporation
are currently being conducted and about 40 % deal with
cancer pathology [39].
4.3.2 Electroporation-based cytokine therapy
Interleukin (IL) 12 possesses very interesting properties to
fight against cancer [47]. Indeed, it favors CD4+ T cell
differentiation into Th1 cells; stimulates cytotoxic functions
of CD8+ T cells, NK cells, and NKT cells, in particular by
increasing IFNγ secretion; and possesses anti-angiogenic
properties.
Heller and colleagues initiated intratumoral administration
in mice of an IL12-encoding plasmid in conjunction with EPs
and demonstrated local and systemic anti-tumor effects in a
murine hepatocellular carcinoma [48]. Interestingly, the
growth of both the treated and distant non-treated tumors
was reduced. Moreover, IFNγ production was increased and
tumor infiltration by NK cells and T cells was reported.
Interestingly, similar observations were made in murine mel-
anoma models [49, 50] with an improved safety as compared
with viral IL12 gene therapy [50]. The enhanced tolerability of
EGT was explained by a local intratumoral confinement of
IL12 when using gene electrotransfer, while IL12 was dissem-
inated into the whole body when using viruses. Indeed, gene
electrotransfer resulted in the transduction of no cells other
than those located in the volume exposed to the EPs.
Toxicological analysis emphasized the safety of the proce-
dure [51], and other preclinical studies supported the efficien-
cy of IL12 EGT on many other tumor models [52], including
in veterinary medicine. In 2008, the first clinical evaluation of
an EGT procedure was performed in the context of an IL12
therapy on patients with metastatic melanoma [53]. Apart
from the discomfort associated with EP delivery, no systemic
side effects were reported. Tumor necrosis and T cell infiltra-
tion were observed, and 10 % of patients with non-
electroporated distant lesions showed complete regression of
all metastases while 42 % displayed a stable disease or partial
response. Four phase II clinical studies are currently being
conducted in patients with squamous cell carcinomas of the
head and neck, metastatic melanoma, Merkel cell cancer, and
cutaneous lymphoma (www.clinicaltrials.gov).
5 Further links between electroporation-based
therapies and immunotherapy
As mentioned in the previous paragraph, EGT strategies are
nowadays mainly focused on immune stimulation.
Interestingly, there is also compelling evidence that the im-
mune system contributes to ECT efficiency.
5.1 ECT and immunogenic cell death
ECT-mediated tumor regression was dramatically decreased
in animals exempt of functional T lymphocytes, in compari-
son to immunocompetent mice [54–56]. Moreover, the edema
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observed following EP delivery on tumors (or any other tis-
sue) was more severe in immunocompetent than in immuno-
deficient mice, consistent with EP-mediated effects that de-
pend on the presence of an intact immune system. The edema,
that increases the vascular permeability, probably paves the
way for the local infiltrates of DCs [57, 58] and lymphocytes
[59] that were found in all ECT-treated tumors starting the
next day after the treatment. Gernili et al. showed that ECT
treatment of human melanoma led to the maturation of
preexisting tumor-resident Langerhans cells, an epidermal
subset of DCs, and to their subsequent migration to the
tumor-draining lymph node as early as 24 h after the treatment
[57]. Similarly, our group detected an intratumoral recruitment
of DCs expressing CD80/CD86 maturation markers 48 h
after the ECT treatment of immunogenic murine tumors in
immunocompetent mice [58]. Sersa et al. demonstrated
that an anti-tumor activity of circulating monocytes and
splenic T lymphocytes was elicited in mice after ECT
treatment of murine SA-1 fibrosarcoma [60]. These studies
highlight an immune system activation after the treatment.
In a very recent study, we deciphered the mechanisms
underlying this immune activation [61]. Indeed, we
showed that ECT induces an immunogenic cancer cell
death through the liberation of ATP and HMGB1 and
the translocation of calreticulin to the cell surface. This
immunogenic cell death elicitation is responsible for the
generation of tumor-specific T cells [62], potentially able
to kill non-ECT-sensitive cancer cells within the primary
tumor. Interestingly, cancer stem cells, thought to be re-
sponsible for cancer recurrence and metastasis [63], seem
sensitive to both extracellular ATP [64] and T cell recog-
nition [65]. Overall, this ECT-driven immune activation
might be at least responsible for the absence of local
relapses (as frequently reported by the physicians practic-
ing ECT) as well as, potentially, for a limitation of meta-
static spreading.
5.2 Adjuvant effect of electric pulses
An increasing number of studies show that delivery of EPs
alone to tissues (normal or tumoral) has also some immuno-
logical effects [66]. These are briefly summarized below.
EP delivery to tissues, in particular muscles, creates an
edema that could facilitate the observed infiltration of macro-
phages, DCs, and polymorphonuclear leukocytes in the EP-
treated volume. It was also found that the expression of clas-
sical APC maturation markers, such as the F4/80 antigen and
MHC class II molecules, was upregulated once APCs were
located in the EP-treated region of the muscles. Consistent
with our previous study demonstrating that intracellular
ATP is released from electroporated cells [61], it can be
hypothesized that EP delivery plays a role of chemoattractant
for DCs and their precursors through the in vivo ATP release.
This release can also favor the differentiation of these precur-
sors and their maturation into DCs with antigen-presenting
capacity. It was also postulated that the immune cell recruit-
ment in the electroporated areas originated from the secretion
of tumor necrosis factor α, interleukin 1β, and other
pro-inflammatory mediators by the electropermeabilized
myocytes. Thus, if an immune stimulation is sought through
EGT, EPs would be more instrumental than expected if only
DNA uptake enhancement is considered.
Consistent with these observations, some authors showed
that APC and polymorphonuclear infiltrates in muscles oc-
curred only when DNA injection was coupled with electropo-
ration [67, 68]. This observation was associated with im-
proved immunization in the context of DNA vaccination.
Finally, our study also showed that in vitro EP delivery on
cells leads to calreticulin exposure on the cell surface [61].
As calreticulin acts as a Beat me^ signal for DCs [62], it can
be speculated that EPs also potentiate the engulfment of the
transfected cells by DCs.
APCs, mostly DCs, are of great importance for the out-
come of vaccination as they ensure effective T cell priming
and maintenance [38]. Therefore, EPs appear to play a pivotal
role in anti-cancer DNA vaccination, not only by enhancing
the transgene expression but also by recruiting APCs in
electroporated tissue areas and by favoring the engulfment
of tumor antigens. Eventually, this is responsible for an im-
proved capacity to mount adaptive immune responses against
tumors.
5.3 Combination of ECTwith immunostimulants
Although ECT is highly efficient on treated nodules, it remains
a local treatment having no apparent anti-tumor effects on non-
treated distant nodules, even though a CD8+ T cell infiltrate
has been observed in these latter [69]. Consequently, it is as-
sumed that the anti-tumor immune responses, raised in the
context of an ECT-driven immunogenic cell death, are not
strong enough to destroy fully established distant tumors.
However, preclinical evidence suggests that the association
of ECT with immunostimulating agents could be an elegant
and efficient way to cure both the ECT-treated nodules and any
distant nodule, should it be undetectable metastasis, even in a
deep-seated area (Table 1).
Pioneer works combining ECT with IL2-based immuno-
therapy led to promising results. IL2 is a T cell proliferation
factor and a cytokine with tumor growth inhibition properties.
Recombinant IL2 administration in combination with ECT
treatment of murine LPB sarcoma tumors led to an increased
rate of tumor cures, as compared with ECT alone [54]. More
strikingly, in a two-tumor model, ECT was combined with
an intratumoral administration of histocompatible IL2-
secreting cells. This resulted in an increased efficiency of
the treatment in the ECT-treated LPB tumors but also
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generated a systemic response as anti-tumor effects were
observed in the contralateral non-ECT-treated tumors [69].
Actually, when the combined treatment was used, contra-
lateral non-ECT-treated tumors were highly infiltrated by
CD4+ and CD8+ T lymphocytes, probably responsible for
the observed 50 % tumor rejection rate of these untreated
contralateral tumors [69]. Similar protocols resulted in
anti-metastatic effects following the treatment of subcuta-
neous murine 3LL Lewis lung carcinoma [70] or VX2
papilloma virus-induced carcinoma transplanted in rabbit’s
liver [71]. Besides, a long-term anti-tumor protection
against recurrence and challenge was conferred in mice
by granulocyte-macrophage colony-stimulating factor or
IL2 gene electrotransfer, in association with ECT treatment
of B16 tumors [72]. In humans, the combination of ECT
and IL2 administration was tested in melanoma patients
and resulted in an increased number of antigens recog-
nized by specific tumor-infiltrating T cells [73]. Although
not verified in the study, one can assume that this T cell
response resulted in cancer cell death within the tumors.
Apart from the IL2-based immunotherapies, TLR9 ligands
(e.g., CpG oligodeoxynucleotides), known to induce Th1
immune responses, were also tested and their injection into
ECT-treated tumors dramatically increased the treatment
efficiency in immunocompetent mice [58]. The ECT/CpG
combination also revealed systemic anti-tumor effects since
tumor growth delays and tumor rejections were observed
in contralateral non-treated tumors. These effects were
even more drastic in highly immunogenic LPB tumors
than in less immunogenic B16 melanoma tumors. No such
systemic effects were observed when ECT alone was ap-
plied. The systemic effects relied, at least partially, on T
cell-mediated immune responses since no effects were ob-
served in nude mice. Furthermore, Sersa et al. showed that
TNFα administration associated with ECT treatment of
murine SA-1 fibrosarcoma also presents interesting bene-
fits, in particular by increasing tumor necrosis and induc-
ing anti-vascular effects [74, 75]. The same group showed
that the combination of ECT with intramuscular IL12 gene
electrotransfer leads to improved cure rates of SA-1 tumors
and TS/A mammary carcinoma in mice [76]. Similarly,
Kishida et al. [77] and Torrero et al. [78] concomitantly treated
Table 1 Overview of already tested combination of electrochemotherapy with immunostimulants
Combinations of interest Species Tumors Comparison with ECT alone References
ECT + recombinant IL2 Mouse LPB fibrosarcoma Increased complete regression rate
Increased tumor growth delay
[54]
Human Metastatic melanoma Non-comparative study [73]
ECT + IL2-secreting cells Mouse LPB fibrosarcoma
3LL Lewis lung carcinoma
Increased complete regression rate
Increased tumor growth delay
Systemic effects (i.e., complete regressions)




Rabbit VX2 papilloma virus-induced carcinoma Increased complete regression rate
Anti-metastatic effects
[71]
ECT + IL2-encoding plasmid Mouse B16 melanoma Increased survival rate
Increased tumor growth delay
[72]
ECT + GM-CSF-encoding plasmid
ECT + recombinant TNFα Mouse SA-1 fibrosarcoma Increased survival rate
Increased tumor growth delay
[74]




ECT + IL12-encoding plasmid Mouse SA-1 fibrosarcoma
TS/A mammary carcinoma
B16 melanoma
4T1 mammary carcinoma SCCVII
squamous cell carcinoma
Increased complete regression rate





Dog Various histological origin Non-comparative study [80]
Dog Various histological origin Non-comparative study [79]
ECT + CpG oligonucleotides Mouse B16 melanoma
LPB fibrosarcoma
Increased complete regression rate
Systemic effects (i.e., complete regressions)
on distant non-treated tumors
Increased tumor growth delay
[58]
ECT + ipilimumab Human Metastatic melanoma Non-comparative study [85]
Human Metastatic melanoma Non-comparative study [84]
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murine B16 melanoma, 4T1mammary carcinoma, or SCCVII
squamous cell carcinoma with ECT and intratumoral IL12
gene electrotransfer. Both studies reported an increased effi-
cacy of the treatment, an inhibition ofmetastasis development,
and a prolonged survival, in comparison with the single-
treatment modalities. These findings were successfully trans-
lated in dogs with spontaneous neoplasms from various ori-
gins [79, 80]. In conclusion, the combination of ECT with
immune stimulation is a very promising avenue for complete
and long-term cancer eradication.
6 Perspectives: immunotherapy, an effective way
to render systemic the efficacy of the ECT
ECT is a very efficient local anti-cancer treatment used for
superficial lesions and being evaluated for deep-seated ones
[2, 23]. It is a very effective tumor-debulking approach
displaying immunostimulating properties through immuno-
genic cell death elicitation [61]. It is considered as a very safe
treatment and is increasingly used in Europe for the palliative
treatment of cutaneous and subcutaneous cancerous nodules.
Fig. 2 Combination of anti-tumor electrochemotherapy with
immunotherapy for long-term and systemic anti-tumor responses. left
Anti-tumor ECT consists in the injection of non- or low-permeant anti-
cancer drugs, such as bleomycin and cisplatin, followed by
electroporation to enhance cell permeability. Because of the direct
cytotoxicity of the drug toward dividing cells, most cancer cells are
driven into death. The remaining viable cancer cells within the treated
tumor can be destroyed by tumor-specific Tcells, primed in the context of
ECT-mediated immunogenic cell death (ICD). Theoretically, these
tumor-specific T cells can also target metastatic nodules, although there
is a lack of direct evidence in the absence of a complementary immune
stimulation. right Immunotherapy agents (e.g., cytokines, therapeutic
antibodies, immune checkpoint blockers, and genes) mount immune
responses that could potentially be synergistic with the one triggered by
ECT. More specifically, immunostimulating EGT triggers specific (DNA
vaccination) or unspecific (cytokine-based EGT) immune responses
against cancer cells leading to their eradication, no matter where they
are located in the body. In all, the combination of ECT with
immunotherapy, including those based on EGT, is an elegant strategy to
treat both the primary tumors and to kill any other cancer cells in the body
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Although a long-lasting response is usually observed locally,
no distant anti-tumor effects in untreated nodules are observed
following ECT treatment alone. Interestingly, preclinical re-
sults sustain the use of immunotherapy in conjunction with
ECT to obtain complete and long-term cancer eradication.
Noteworthy, some recent immunotherapy approaches have
shown promising results for cancer treatment and constitute
seducing approaches to restore or strengthen anti-tumor im-
munity [81]. For example, ipilimumab is a monoclonal anti-
body administered to patients with metastatic melanoma [82],
a tumor extensively studied in the field of ECT. Ipilimumab is
directed against cytotoxic T lymphocyte-associated protein 4
(CTLA4) on T cells which turns down the T cell effector
functions. Similarly, anti-programmed cell death protein 1
(PD1) antibodies are also of great interest as they prevent
the inhibitory effect on T cell functions of the interaction
between PD1 (on T cells) and PD1 ligand (on tumor cells)
[83]. Hence, a combination of ECT with anti-CTLA4 or
anti-PD1 antibodies could be an elegant way to destroy
the initial nodule while raising efficient anti-tumor re-
sponses to ultimately eliminate remaining and circulating
cancer cells. In this spirit, two recent studies seeking to
evaluate the potency of the combination of ipilimumab
and ECT showed very encouraging results [84, 85]. In
the case report published by Brizio et al. [84], local
ECT treatment of cutaneous lesions of melanoma was
followed by ipilimumab administration, resulting in the
complete regression of all the cutaneous and visceral me-
tastases for at least 1 year. Interestingly, vitiligo-like le-
sions developed exclusively around the sites of previous
ECT, suggesting that a prior ECT-driven immune activa-
tion was enhanced by ipilimumab. The other study report-
ed that the volume of distant non-ECT-treated tumors de-
creased or was stabilized in nine patients out of 15, pos-
sibly through ipilimumab-induced regulatory T cell deple-
tion [85]. Of course, as presented in the previous paragraph,
ECT could also be associated with other immunostimulating
agents, such as cytokines with anti-tumor properties.
Alternatively, immune stimulation through EGT has also re-
cently raised great hope for the treatment of cancer [53]. EGT
appears safe, and besides their ability to enhance the DNA
uptake, EPs may potentiate the beneficial outcome of
immunostimulating EGT, notably of DNA vaccination,
through immunological adjuvant effects [66]. Further studies
are urgently needed to confirm the valuable therapeutic poten-
tial of all these combinations. It is conceivable that a combi-
nation of tumor-debulking ECTwith immunostimulating EGT
could get the patients rid of not only the primary tumors and
accessible metastases (like by using surgery) but also all of the
non-accessible metastases and micrometastases, thus hamper-
ing cancer chronicity (Fig. 2). ECT electrochemotherapy, IL
interleukin, GM-CSF granulocyte-macrophage colony-stimu-
lating factor, TNF tumor necrosis factor.
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